What is the debt of Biocept this year?
Biocept has a debt level of -10.48 USD this year.
Biocept Debt 2025
Biocept Debt
-10.48 USD
Ticker
BIOC
ISIN
US09072V5012
WKN
A2QEQE
In 2025, Biocept's total debt was -10.48 USD, a 0% change from the 0 USD total debt recorded in the previous year.
Biocept Aktienanalyse
What does Biocept do?
Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Biocept's Debt Structure
Biocept's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Biocept's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Biocept’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Biocept’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Biocept stock
What was the debt of Biocept compared to the previous year?
The debt of Biocept has increased by 0% compared to the previous year dropped.
What are the consequences of high debt for investors in Biocept?
High debt can pose a risk for investors of Biocept, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Biocept?
Low debt means that Biocept has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Biocept affect the company?
An increase in debt of Biocept can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Biocept affect the company?
A reduction in debt of Biocept can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Biocept?
Some factors that can influence the debt of Biocept include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Biocept so important for investors?
The debts of Biocept are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Biocept take to change the debt?
To change the debt, Biocept can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Biocept pay?
Over the past 12 months, Biocept paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biocept is expected to pay a dividend of 0 USD.
What is the dividend yield of Biocept?
The current dividend yield of Biocept is .
When does Biocept pay dividends?
Biocept pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biocept?
Biocept paid dividends every year for the past 0 years.
What is the dividend of Biocept?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biocept located?
Biocept is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biocept kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biocept from 9/26/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2025.
When did Biocept pay the last dividend?
The last dividend was paid out on 9/26/2025.
What was the dividend of Biocept in the year 2024?
In the year 2024, Biocept distributed 0 USD as dividends.
In which currency does Biocept pay out the dividend?
The dividends of Biocept are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Biocept
Our stock analysis for Biocept Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocept Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
